BioAI Health

BioAI is a leading provider of multimodal artificial intelligence (AI) solutions for digital health in precision medicine. The company develops novel predictive tests and digital biomarkers to improve cancer treatment decisions and patient outcomes. BioAI's technology employs an ensemble AI approach, blending deep learning and probabilistic programming, to uncover dependencies in complex biomedical data. This enables the precise identification of molecular signals and regions in tumor tissues using single-cell RNA-seq and spatial transcriptomics, enhancing biomarker discovery and prediction in digital pathology.

BioAI offers the PredictX Platform, leveraging its in-silico phenotype projection technology powered by advanced Causal AI. This technology facilitates the derivation of informative gene interaction networks based on conditional gene state probabilities, without prior biological knowledge. By uncovering deep biological insights and identifying potential therapeutic targets from complex data, BioAI's causal AI technology streamlines the biopharmaceutical drug discovery process, enabling the development of novel, effective drugs with fewer side effects.

BioAI's solutions include building novel precision diagnostic assays, expanding access to eligible patients for clinical studies through rapid, globally accessible, and cost-efficient H&E-based screening, and matching patients to the most effective therapies. The company acquired Panakeia Technologies, Ltd in London in March 2023.